<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chloral hydrate (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chloral hydrate (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chloral hydrate (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9239" href="/d/html/9239.html" rel="external">see "Chloral hydrate (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="11235" href="/d/html/11235.html" rel="external">see "Chloral hydrate (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866283"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Chloral Hydrate Odan;</li>
<li>PMS-Chloral Hydrate [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051645"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Hypnotic</span>;</li>
<li>
<span class="list-set-name">Sedative</span></li></ul></div>
<div class="block don drugH1Div" id="F53462402"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Commercially available product no longer available in the United States.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fccfba2d-9aef-4d27-8cde-95a73ad46a32">Sedation, procedural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, procedural (eg, echocardiogram or EEG):</b> Limited data available: Oral: 25 to 50 mg/kg/dose once prior to procedure (Fuhrman 2011; Krauss 2006; Rudolph 1996).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F149279"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Commercially available product no longer available in the United States.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eebde992-d4c4-4a2d-8298-3c4812cd280a">Sedation, mechanically ventilated patient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, mechanically ventilated patient:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 8 to 25 mg/kg/dose every 6 to 8 hours; titrate to effect based on patient response up to 50 mg/kg/dose every 6 hours; maximum dose: 1,000 mg/dose (Parkinson 1997; manufacturer's labeling). Dosing based on randomized controlled trial of 44 patients (age range: 1 day to 15 years) that compared continuous infusion midazolam (n=20) to promethazine plus chloral hydrate (n=23) at a dose of 25 mg/kg/dose every 6 hours for sedation in ventilated patients. If sedation unsatisfactory, doses could be increased up to 50 mg/kg/dose every 6 hours. The total number of satisfactory sedation assessments was significantly higher in the chloral hydrate/promethazine group (61%) compared to the midazolam group (48%) (Parkinson 1997).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fccfba2d-9aef-4d27-8cde-95a73ad46a32">Sedation, procedural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, procedural (eg, echocardiogram or EEG):</b> Limited data available: Infants and Children (best results in children &lt;3 years of age): Oral: 25 to 100 mg/kg/dose 10 to 30 minutes prior to procedure; maximum dose: 1,000 mg/dose; may repeat after 30 minutes with 25 to 50 mg/kg/dose if necessary. Maximum total dose: 100 mg/kg/procedure or 2,000 mg/procedure (Derakhshani 2022; Heistein 2006; Krauss 2006; Napoli 1996; Wheeler 2001). <b>Note:</b> Although dosing may be used in adolescent patients, use in these patients is not common; older children and adolescent patients may not require sedation for echocardiogram and other agents should be used for EEG.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084450"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in patients with marked renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Dialyzable.</p></div>
<div class="block dohp drugH1Div" id="F51108484"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use is contraindicated in patients with marked hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F149267"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9239" href="/d/html/9239.html" rel="external">see "Chloral hydrate (United States: Not available): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e957755b-7e6a-4c47-abc7-399e245a30c5">Procedural sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation: Note: </b>Not routinely used in adults; other agents are preferred for procedural sedation (ASA 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg to 1 <b>g</b> once; administer 30 minutes prior to surgery/procedure.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991002"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:0em;">CrCl &lt;50 mL/minute: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988180"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F149231"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial arrhythmia, depression of myocardial contractility, hypotension, shortening of refractory periods, supraventricular tachycardia (infants and children) (Hirsch 1986), torsades de pointes, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin rash (including bullous dermatitis, eczema, erythema multiforme, erythema of skin, scarlatiniform rash, urticaria)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acute intermittent porphyria, ketonuria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, flatulence, gastric irritation, intestinal obstruction (infants), nausea, unpleasant taste, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, nonthrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Yoo 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (staggering), ataxia, confusion, delirium, dizziness, drowsiness, drug dependence, excitement, hallucinations, hangover effect, malaise, nightmares, seizure (Muñoz 1997), somnambulism, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Allergic conjunctivitis, blepharoptosis, keratoconjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Increased middle ear pressure (infants and children)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Airway obstruction (young children), laryngeal edema (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug tolerance, paradoxical reaction (Slatt 2009)</p></div>
<div class="block coi drugH1Div" id="F149248"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to chloral hydrate or any component of the formulation; marked hepatic or renal impairment</p></div>
<div class="block war drugH1Div" id="F149228"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Avoid use in patients with severe cardiac disease; larger doses may precipitate arrhythmias and hypotension (Fazio 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disorders: Because of irritant properties, avoid use in patients with gastritis, esophagitis, or gastric/duodenal ulcer (Joffe 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Although manufacturer labeling suggests choral hydrate may precipitate attacks of acute intermittent porphyria and to use with caution, chloral hydrate is considered to be safe based on evidence and expert consensus (Porphyria Foundation) (Crimlisk 1997; Gorchein 1997; Jensen 1995; Porphyria Foundation 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Closely monitor patients with respiratory insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Children: Life-threatening respiratory obstruction and deaths have been reported with use in children; use with extreme caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Excessive sedation or other adverse effects may be more likely to occur in elderly patients; avoid use in older adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Prolonged use in neonates is associated with direct hyperbilirubinemia (active metabolite [TCE] competes with bilirubin for glucuronide conjugation in the liver).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: May be habit forming; long-term use or larger than therapeutic doses may result in tolerance and in physical and/or psychological dependance. Use with caution in patients with a history of substance abuse disorder, mentally depressed, or suicidal. Sudden withdrawal may result in hallucinations and symptoms similar to delirium tremens (sometimes fatal); taper chloral hydrate gradually.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878378"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Deaths and permanent neurologic injury from respiratory compromise have been reported in children sedated with chloral hydrate; respiratory obstruction may occur in children with tonsillar and adenoidal hypertrophy, obstructive sleep apnea, and Leigh encephalopathy, and in ASA class III children; depressed levels of consciousness may occur; chloral hydrate should not be administered for sedation by nonmedical personnel or in a nonsupervised medical environment; sedation with chloral hydrate requires careful patient monitoring (Coté 2000). Animal studies suggest that chloral hydrate may depress the genioglossus muscle and other airway-maintaining muscles in patients who are already at risk for life-threatening airway obstruction (eg, obstructive sleep apnea); alternative sedative agents should be considered for these patients (Hershenson 1984).</p></div>
<div class="block prod-avail drugH1Div" id="F25590818"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F44327085"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52866284"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/5 mL (500 mL)</p></div>
<div class="block admp drugH1Div" id="F52612397"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Minimize unpleasant taste and gastric irritation by administering with water, infant formula, fruit juice, or ginger ale.</p></div>
<div class="block adm drugH1Div" id="F149245"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May dilute syrup in water or other oral liquid (eg, fruit juice, ginger ale) to minimize gastric irritation; administer 30 minutes prior to surgery/procedure.</p></div>
<div class="block sts drugH1Div" id="F149259"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store syrup below 40°C (104°F) preferably between 15°C and 30°C (59°F and 86°F). Store in a tight, light-resistant container; protect from freezing.</p></div>
<div class="block usep drugH1Div" id="F53565993"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Sedative/hypnotic for surgeries and diagnostic procedures or EEG evaluations in children and adults. Sedative for mechanically ventilated infants, children, and adolescents. <b>Note:</b> Within the United States, there are no longer any FDA-approved commercially available preparations.</p></div>
<div class="block mst drugH1Div" id="F5174520"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (for sedation of children) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299013"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F149233"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the adverse/toxic effect of Chloral Hydrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Hypnotics (Nonbenzodiazepine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Chloral Hydrate may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F13447510"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Chloral hydrate crosses the placenta, and long-term use may lead to withdrawal symptoms in the neonate.</p></div>
<div class="block mopp drugH1Div" id="F53565974"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Level of sedation; vital signs, heart rhythm (with long-term use), and O<sub>2</sub> saturation.</p></div>
<div class="block pha drugH1Div" id="F149227"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Central nervous system depressant effects are due to its active metabolite trichloroethanol, mechanism unknown</p></div>
<div class="block phk drugH1Div" id="F149247"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 15 to 30 minutes (Krauss 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 1 to 2 hours (Krauss 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Trichloroethanol: 35% to 40%; trichloroacetic acid: ∼94% (may compete with bilirubin for albumin binding sites)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly metabolized in the liver by alcohol dehydrogenase to trichloroethanol (active metabolite); trichloroethanol undergoes glucuronidation in the liver; variable amounts hepatically and renally to trichloroacetic acid (inactive)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Chloral hydrate (Mayer 1991):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm infants (postmenstrual age [PMA] 31 to 37 weeks): 1.01 ± 0.97 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Term infants (PMA 38 to 42 weeks): 3.01 ± 5.81 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;14 years: 9.68 ± 7.73 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Active metabolite (trichloroethanol) (Mayers 1991):</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm infants (PMA 31 to 37 weeks): 39.82 ± 14.27 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Term infants (PMA 38 to 42 weeks): 27.8 ± 21.32 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;14 years: 9.67 ± 1.72 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 8 to 12 hours (Fuhrman 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Trichloroacetic acid: Adults: 67 hours (Furhman 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites); feces (small amounts)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038557"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Noctec</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Chloraldurat blau | Chloraldurat rot | Medianox</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Chloraldurat | Chloralhydrat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Chloral | Noctec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Chloral</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Chloral</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Escre aventis | Escre s.s. seiyaku</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pocral</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Biomed Chloral Hydrate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Apnotek</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Somnote</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Chloral</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatric Dentistry. Guideline for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. 2011;35(6):205-221.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26446832">
<a name="26446832"></a>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults [published online October 8, 2015]. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/26446832/pubmed" id="26446832" target="_blank">26446832</a>]</span>
<span class="doi">10.1111/jgs.13702</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Chloral hydrate oral liquid [prescribing information]. Edmond, OK: International Journal of Pharmaceutical Compounding, Inc; November/December 2006.</div>
</li>
<li>
<div class="reference">
                  Chloral hydrate syrup [prescribing information]. Pointe Claire, Quebec, Canada: Odan Laboratories; May 2003.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11015502">
<a name="11015502"></a>Coté CJ, Karl HW, Notterman DA, et al. Adverse Sedation Events in Pediatrics: Analysis of Medications Used for Sedation. <i>Pediatrics.</i> 2000;106(4):633-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/11015502/pubmed" id="11015502" target="_blank">11015502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120442">
<a name="9120442"></a>Crimlisk HL. The little imitator--porphyria: a neuropsychiatric disorder. <i>J Neurol Neurosurg Psychiatry</i>. 1997;62(4):319-328. doi:10.1136/jnnp.62.4.319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/9120442/pubmed" id="9120442" target="_blank">9120442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36741200">
<a name="36741200"></a>Derakhshani F, Sabzeghabaie M, Ghazavi M. Nasal dexmedetomidine in sedation of electroencephalogram (EEG) in comparison with chloral hydrate as a clinical trial. <i>Int J Physiol Pathophysiol Pharmacol</i>. 2022;14(6):296-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/36741200/pubmed" id="36741200" target="_blank">36741200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23675554">
<a name="23675554"></a>Fazio G, Vernuccio F, Grutta G, Re GL. Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management. <i>World J Cardiol</i>. 2013;5(4):87-93. doi:10.4330/wjc.v5.i4.87<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/23675554/pubmed" id="23675554" target="_blank">23675554</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Philadelphia, PA: Elsevier Health; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9384458">
<a name="9384458"></a>Gorchein A. Drug treatment in acute porphyria. <i>Br J Clin Pharmacol</i>. 1997;44(5):427-434. doi:10.1046/j.1365-2125.1997.t01-1-00609.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/9384458/pubmed" id="9384458" target="_blank">9384458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31447530">
<a name="31447530"></a>Grissinger M. Chloral hydrate: is it still being used? Are there safer alternatives? <i>P T</i>. 2019;44(8):444-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/31447530/pubmed" id="31447530" target="_blank">31447530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16481449">
<a name="16481449"></a>Heistein LC, Ramaciotti C, Scott WA, Coursey M, Sheeran PW, Lemler MS. Chloral hydrate sedation for pediatric echocardiography: physiologic responses, adverse events, and risk factors. <i>Pediatrics</i>. 2006;117(3):e434-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/16481449/pubmed" id="16481449" target="_blank">16481449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6739190">
<a name="6739190"></a>Hershenson M, Brouillette RT, Olsen E, et al, “The Effect of Chloral Hydrate on Genioglossus and Diaphragmatic Activity,” <i>Pediatr Res</i>, 1984, 18(6):516-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/6739190/pubmed" id="6739190" target="_blank">6739190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3706808">
<a name="3706808"></a>Hirsch IA, Zauder HL. Chloral hydrate: a potential cause of arrhythmias. <i>Anesth Analg</i>. 1986;65(6):691-692.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/3706808/pubmed" id="3706808" target="_blank">3706808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7864431">
<a name="7864431"></a>Jensen NF, Fiddler DS, Striepe V. Anesthetic considerations in porphyrias. <i>Anesth Analg</i>. 1995;80(3):591-599. doi:10.1097/00000539-199503000-00028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/7864431/pubmed" id="7864431" target="_blank">7864431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29178963">
<a name="29178963"></a>Joffe AR, Hogan J, Sheppard C, Tawfik G, Duff JP, Garcia Guerra G. Chloral hydrate enteral infusion for sedation in ventilated children: the CHOSEN pilot study. <i>Crit Care</i>. 2017;21(1):290. doi:10.1186/s13054-017-1879-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/29178963/pubmed" id="29178963" target="_blank">29178963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780. DOI: 10.1016/S0140-6736(06)68230-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1914781">
<a name="1914781"></a>Mayers DJ, Hindmarsh KW, Sankaran K, Gorecki DK, Kasian GF. Chloral hydrate disposition following single-dose administration to critically ill neonates and children. <i>Dev Pharmacol Ther</i>. 1991;16(2):71-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/1914781/pubmed" id="1914781" target="_blank">1914781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9403671">
<a name="9403671"></a>Muñoz M, Gómez A, Soult JA, et al. Seizures caused by chloral hydrate sedative doses. <i>J Pediatr</i>. 1997;131(5):787-788. doi:10.1016/s0022-3476(97)70119-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/9403671/pubmed" id="9403671" target="_blank">9403671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8765629">
<a name="8765629"></a>Napoli KL, Ingall CG, Martin GR. Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography. <i>J Pediatr</i>. 1996;129(2):287-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/8765629/pubmed" id="8765629" target="_blank">8765629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9308065">
<a name="9308065"></a>Parkinson L, Hughes J, Gill A, Billingham I, Ratcliffe J, Choonara I. A randomized controlled trial of sedation in the critically ill. <i>Paediatr Anaesth</i>. 1997;7(5):405-410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/9308065/pubmed" id="9308065" target="_blank">9308065</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  pms-Chloral hydrate [product monograph]. Montreal, Canada: Pharmascience; May 1998.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PF.1">
<a name="PF.1"></a>Porphyria Foundation. Porphyria drug safety database. https://www.porphyriafoundation.org/drugSafety_listAll.cfm. Accessed June 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29334501">
<a name="29334501"></a>Practice guidelines for moderate procedural sedation and analgesia 2018: a report by the American Society of Anesthesiologists Task Force on moderate procedural sedation and analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. <i>Anesthesiology</i>. 2018;128(3):437-479. doi:10.1097/ALN.0000000000002043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/29334501/pubmed" id="29334501" target="_blank">29334501</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rudolph A, Hoffman J, Rudolph C eds.<i> Rudolph's Pediatrics</i>. 20th ed. Stamford, CT: Appleton &amp; Lange; 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18853708">
<a name="18853708"></a>Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. <i>J Clin Sleep Med</i>. 2008;4(5):487-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/18853708/pubmed" id="18853708" target="_blank">18853708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19696608">
<a name="19696608"></a>Slatt KA. Crazy with chloral hydrate: a parent witnesses a paradoxical reaction. <i>Gastroenterol Nurs</i>. 2009;32(4):296-297. doi:10.1097/SGA.0b013e3181b2c936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/19696608/pubmed" id="19696608" target="_blank">19696608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24843805">
<a name="24843805"></a>Yoo SD, Kim SG, Kim SH, Kim HY. Drug rash with eosinophilia and systemic symptoms syndrome induced by chloral hydrate in early childhood. <i>Allergy Asthma Immunol Res</i>. 2014;6(3):270-272. doi:10.4168/aair.2014.6.3.270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/24843805/pubmed" id="24843805" target="_blank">24843805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11491133">
<a name="11491133"></a>Wheeler DS, Jensen RA, Poss WB. A randomized, blinded comparison of chloral hydrate and midazolam sedation in children undergoing echocardiography. <i>Clin Pediatr (Phila)</i>. 2001;40(7):381-387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloral-hydrate-united-states-not-available-pediatric-drug-information/abstract-text/11491133/pubmed" id="11491133" target="_blank">11491133</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13143 Version 215.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
